Gilead Sciences reported strong Q3 results with revenue of $8.3 billion, beating analyst expectations and showing growth both quarterly and yearly. Sales of Trodelvy, a breast cancer drug, rose 41.7% year-over-year to $506 million. The company also agreed to acquire PepStar's oral IL-23R inhibitor program for $1.275 billion upfront, signaling expansion in its drug pipeline. Gilead trades at a favorable valuation compared to its sector, supporting a 'Buy' rating from analysts.
Gilead Sciences shares are up 5.63% on Pluang, trading at USD 174.94 as of Oct 30, 2026 18:11 WIB. The stock shows strong investor interest with 81% of order activity on Pluang being buys and a market cap of $205.35 billion at that time.
Gilead Sciences reported strong Q3 results with growth in HIV treatments and oncology drugs like Trodelvy. However, Medicare pricing changes will cut Biktarvy revenue by $1.5 billion annually starting in 2028, increasing Gilead's dependence on HIV pr...
Assembly Biosciences has dosed the first two participants in a Phase 2 study of ABI-6250, an oral small-molecule drug for chronic hepatitis delta virus (HDV) infection. The study will enroll about 80 participants to evaluate safety, pharmacokinetics,...
Eli Lilly, Merck, and Gilead Sciences are set to report their Q3 2026 earnings on October 29, with Eli Lilly facing lowered EPS estimates amid strong GLP-1 drug demand, Merck dealing with tough comparisons for its cancer drug Keytruda, and Gilead man...
